Development of Ligand-Transformed Alpha-Fetoprotein for Use Against Breast Cancer in Humans
Annual rept. 1 Jul 96-30 Jun 97
ALBANY MEDICAL COLL NY
Pagination or Media Count:
During the first two years of this project, we established that nanogram quantities of ligand- activated and microgram quantities of unactivated natural and recombinant human AFP inhibited growth of estrogen-dependent MCF-7 human breast cancer. During year three of this project we have established that other estrogen-dependent human breast cancers as well as androgen-dependent human prostate cancer are growth-inhibited by microgram doses of unactivated natural human AFP. Hormone-independent human breast, ovarian, uterine and prostate cancers were not growth-inhibited by AFP. The histopathology of tumors growth-inhibited by AFP continues to be a profile of cytostasis with an accumulation of cells in G0G1 and no evidence of necrosis. Receptor for sex steroid hormone appears to be a marker for tumor sensitivity to AFP. Elevation in serum FSH and E2 levels are intermediate markers for in vivo effect of AFP against estrogen-dependent responses. Truncated forms of AFP have activity similar to that of the full-length molecule. There has been no evidence of host toxicity during therapeutic application of the active forms of AFP.
- Genetic Engineering and Molecular Biology
- Medicine and Medical Research